RM Financial Services LLC Makes New Investment in IDEXX Laboratories, Inc. $IDXX

RM Financial Services LLC acquired a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 925 shares of the company’s stock, valued at approximately $626,000.

A number of other institutional investors have also recently modified their holdings of IDXX. Vanguard Group Inc. grew its holdings in shares of IDEXX Laboratories by 0.9% during the 3rd quarter. Vanguard Group Inc. now owns 9,962,025 shares of the company’s stock worth $6,364,638,000 after purchasing an additional 86,040 shares in the last quarter. Elyxium Wealth LLC acquired a new position in IDEXX Laboratories in the fourth quarter valued at about $3,666,459,000. Geode Capital Management LLC lifted its position in IDEXX Laboratories by 3.5% during the fourth quarter. Geode Capital Management LLC now owns 2,583,939 shares of the company’s stock worth $1,749,380,000 after purchasing an additional 86,263 shares during the period. Northwestern Mutual Wealth Management Co. lifted its position in IDEXX Laboratories by 63,503.9% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,444,445 shares of the company’s stock worth $977,210,000 after purchasing an additional 1,442,174 shares during the period. Finally, Invesco Ltd. grew its stake in IDEXX Laboratories by 14.0% during the third quarter. Invesco Ltd. now owns 1,320,263 shares of the company’s stock worth $843,503,000 after buying an additional 161,782 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have commented on IDXX shares. Citigroup assumed coverage on shares of IDEXX Laboratories in a report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 target price on the stock. UBS Group reduced their price target on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 28th. Stifel Nicolaus lowered their price objective on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research report on Tuesday, March 31st. Weiss Ratings cut IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 11th. Finally, Wall Street Zen lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Seven research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and a consensus target price of $751.00.

IDEXX Laboratories Trading Down 3.8%

IDXX opened at $556.94 on Thursday. The company’s 50 day moving average is $563.22 and its 200-day moving average is $629.35. IDEXX Laboratories, Inc. has a 1-year low of $506.91 and a 1-year high of $769.98. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. The company has a market cap of $43.93 billion, a P/E ratio of 41.01, a PEG ratio of 3.17 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. The business had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The firm’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same period in the prior year, the company earned $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Equities research analysts predict that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.